checkAd

Kiadis employee options committed under the Sanofi Offer

Nachrichtenquelle: globenewswire
09.04.2021, 07:00  |  114   |   |   

This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis launched on February 12, 2021 (the “Offer”). The Offer is made only by means of the offer memorandum approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on February 10, 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on February 11, 2021 (the “Offer Memorandum”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Capitalized terms used but not defined in this press release will have the meaning given thereto in the Offer Memorandum.

Kiadis employee options committed under the Sanofi Offer
48.80% of Fully Diluted share capital now committed under the Offer

Amsterdam, The Netherlands, April 9, 2021 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) today announces that all Kiadis employee options with an exercise price below the Offer Price are committed under Sanofi’s Offer, resulting in approximately 48.80% of the Fully Diluted share capital of Kiadis now being committed under the Offer.

None of the holders of options on ordinary shares of Kiadis stock or stock appreciation rights under the Kiadis 2016 Share Option and Stock Appreciation Right Plan with an exercise price below the Offer Price (“Options”), decided to opt-out during the opt-out period that ended yesterday. Therefore, on the terms and subject to the conditions described in Section 7.9 (Options and SARs) of the Offer Memorandum, the 7,446,147 ordinary shares of Kiadis stock resulting from the exercise of such Options are now committed under the Offer, which is approximately 12.20% of the issued and outstanding ordinary shares of Kiadis stock (on a Fully Diluted basis).

Together with the irrevocable undertakings given by (i) Empery Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax Efficient III, LP; (ii) funds managed by Life Sciences Partners; (iii) former CytoSen Therapeutics Inc. shareholders and option holders; and (iv) Kreos Capital V (UK) Limited, approximately 48.80% of the issued and outstanding ordinary shares of Kiadis stock, calculated on a Fully Diluted basis, are now committed under the Offer.

Seite 1 von 4
Kiadis Pharma Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Kiadis employee options committed under the Sanofi Offer This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the public offer by …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel